ORIFARM GENERICS A/S: Financial statements 2021
CVR: 25674030
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2021. In 2021, the company reported revenue of DKK 1,757,348,000 and a net result of DKK 150,140,000 compared with DKK 145,514,000 the year before. That is an increase of 155.3% compared with the year before. The profit margin was 8.5%. Equity in the 2021 report amounted to DKK 527,257,000. The solvency ratio was 45%. The company had 181 employees in the financial year.
- Revenue
- DKK 1,757,348,000
- Gross Profit
- DKK 329,329,000
- Profit/Loss
- DKK 150,140,000
- Equity
- DKK 527,257,000
- Total Assets
- DKK 1,172,126,000
- Employees
- 181
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | 1.8B | 329.3M | 150.1M | 527.3M | 181 |
| 2020 | 688.4M | 274.2M | 145.5M | 201.2M | 117 |
| 2019 | 545M | 197M | 103.9M | 145.7M | 99 |
| 2018 | 504.4M | 162.7M | 70.1M | 116.8M | 102 |
| 2017 | - | 172M | 76.4M | 86.8M | 97 |
Official annual report
Find more companies like ORIFARM GENERICS A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
ORIFARM GENERICS A/S has published its annual report for 2020. Revenue came to DKK 688,426,000, and the net result was DKK 145,514,000.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.